Skip to content
The Policy VaultThe Policy Vault

Rydapt (midostaurin capsules) — Cigna

Acute Myeloid Leukemia

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has FLT3 mutation-positive disease as detected by an approved test

Approval duration

1 year